GlassScriptPhysician profile
Malin Adams
NPI 1437824224
$964.99
in general payments reported to CMS, 2019-2025
14 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.80 · 2024: $119 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $215.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.95 | 2025 | Eohilia, Entyvio |
| Abbvie INC. | $117.64 | 2025 | |
| Qol Medical, LLC | $84.75 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $71.01 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $69.35 | 2025 | Rezdiffra |
| Novo Nordisk INC | $56.55 | 2025 | Wegovy |
| Janssen Biotech, INC. | $48.63 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $45.12 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.70 | 2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $23.31 | 2025 | Vowst |
| Gilead Sciences, INC. | $21.30 | 2025 | |
| Boston Scientific Corporation | $18.80 | 2023 | |
| Ardelyx, INC. | $18.06 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malin Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.